Publicado 6 números por año
ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472
Indexed in
Gene Expression Signatures of Interleukin-2 In Vivo and In Vitro and Their Relation to Anticancer Therapy
SINOPSIS
Treatment with human recombinant interleukin−2 (rIL−2) can successfully eradicate advanced cancer in humans; however, its utilization is limited by the unpredictability of its effectiveness and the excessive toxicity often associated with its use. The mechanisms responsible for immune-mediated tumor regression and those associated with limiting toxicity have not yet been sorted out. Thus, this review critically addresses what has been done in the past to understand this biologically and practically important question and discusses future strategies to enhance the understanding of this interesting model of immune-mediated tumor rejection. In particular, the first aim of this review is to discuss what is known about the mechanism(s) responsible for tumor rejection; the second aim is to review the relationship between the toxicity induced by rIL−2 treatment and its effectiveness; the third aim is to summarize novel insights into the possible mechanism of rIL−2 activity in vivo using high-throughput strategies aimed at the global assessment in real-time of events associated with rIL−2 therapy in humans. This information will not only lead to a better utilization of this biological agent in clinical practice but it may also provide important information about how immune-mediated tissue rejection occurs.
-
Lech Patrycja J, Russell Stephen J, Use of attenuated paramyxoviruses for cancer therapy, Expert Review of Vaccines, 9, 11, 2010. Crossref
-
Öhlschläger Peter, Quetting Michael, Alvarez Gerardo, Dürst Matthias, Gissmann Lutz, Kaufmann Andreas M., Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants, International Journal of Cancer, 125, 1, 2009. Crossref
-
Stern Eric, Vacic Aleksandar, Li Chao, Ishikawa Fumiaki N., Zhou Chongwu, Reed Mark A., Fahmy Tarek M., A Nanoelectronic Enzyme-Linked Immunosorbent Assay for Detection of Proteins in Physiological Solutions, Small, 6, 2, 2010. Crossref
-
Decker William K., Safdar Amar, Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited, Cytokine & Growth Factor Reviews, 20, 4, 2009. Crossref
-
al-Ramadi Basel K., Fernandez-Cabezudo Maria J., El-Hasasna Hussain, Al-Salam Suhail, Bashir Ghada, Chouaib Salem, Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis, Clinical Immunology, 130, 1, 2009. Crossref
-
Potala Sirisha, Sahoo Sanjeeb K., Verma Rama S., Targeted therapy of cancer using diphtheria toxin-derived immunotoxins, Drug Discovery Today, 13, 17-18, 2008. Crossref
-
Wang Ena, Marincola Francesco M., From the “Delayed Allergy Reaction” to the “Immunologic Constant of Rejection”, in Immunologic Signatures of Rejection, 2011. Crossref
-
Bedognetti Davide, Signatures Associated with Acute Rejection: Allograft Rejection, in Immunologic Signatures of Rejection, 2011. Crossref
-
Hu Yu-Lan, Huang Bin, Zhang Tian-Yuan, Miao Pei-Hong, Tang Gu-Ping, Tabata Yasuhiko, Gao Jian-Qing, Mesenchymal Stem Cells as a Novel Carrier for Targeted Delivery of Gene in Cancer Therapy Based on Nonviral Transfection, Molecular Pharmaceutics, 9, 9, 2012. Crossref
-
Spivey Tara L, Uccellini Lorenzo, Ascierto Maria Libera, Zoppoli Gabriele, De Giorgi Valeria, Delogu Lucia Gemma, Engle Alyson M, Thomas Jaime M, Wang Ena, Marincola Francesco M, Bedognetti Davide, Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis, Journal of Translational Medicine, 9, 1, 2011. Crossref
-
Sabatino Marianna, Kim-Schulze Seunghee, Panelli Monica C., Stroncek David, Wang Ena, Taback Bret, Kim Dae Won, DeRaffele Gail, Pos Zoltan, Marincola Francesco M., Kaufman Howard L., Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy, Journal of Clinical Oncology, 27, 16, 2009. Crossref